Recro Pharma, Inc. (REPH) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS
Recro Pharma, Inc. (NASDAQ:REPH) posted its earnings results on Thursday. The specialty pharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.06, MarketWatch Earnings reports. Recro Pharma had a negative return on equity of 61.09% and a negative net margin of 45.15%. The firm had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.90 million.
Shares of Recro Pharma (NASDAQ REPH) traded up 0.68% during midday trading on Friday, reaching $7.35. The company’s stock had a trading volume of 31,500 shares. The firm’s 50 day moving average is $7.37 and its 200 day moving average is $7.64. The firm’s market capitalization is $140.02 million. Recro Pharma has a 52 week low of $5.81 and a 52 week high of $10.85.
Several equities research analysts have weighed in on the company. Roth Capital set a $20.00 price target on Recro Pharma and gave the stock a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies set a $11.00 price target on Recro Pharma and gave the stock a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research downgraded Recro Pharma from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Janney Montgomery Scott downgraded Recro Pharma from a “buy” rating to a “fair value” rating and cut their price target for the stock from $21.00 to $6.50 in a report on Wednesday, June 14th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $14.00.
In related news, insider James E. Flynn sold 110,447 shares of the business’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $6.39, for a total value of $705,756.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder James E. Flynn sold 32,447 shares of the business’s stock in a transaction dated Tuesday, June 13th. The stock was sold at an average price of $6.59, for a total value of $213,825.73. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 215,762 shares of company stock worth $1,430,830. 21.60% of the stock is currently owned by insiders.
WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/recro-pharma-inc-reph-announces-quarterly-earnings-results-beats-estimates-by-0-06-eps.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.